Anavex Life Sciences Corp.
AVXL · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $103 | $132 | $151 | $149 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $1 | $2 | $3 | $3 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $0 | $1 | $1 | $0 |
| Total Curr. Assets | $104 | $136 | $154 | $153 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $3 | $3,547 |
| Total NC Assets | $0 | $0 | $3 | $3,547 |
| Other Assets | $0 | $0 | -$3 | -$3,547 |
| Total Assets | $104 | $136 | $154 | $153 |
| Liabilities | – | – | – | – |
| Payables | $4 | $10 | $4 | $4 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $1 | $1 | $0 | $0 |
| Other Curr. Liab. | $4 | $5 | $8 | $6 |
| Total Curr. Liab. | $9 | $15 | $13 | $10 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $9 | $15 | $13 | $10 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$382 | -$336 | -$293 | -$246 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $477 | $456 | $435 | $388 |
| Total Equity | $95 | $120 | $142 | $142 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $104 | $136 | $154 | $153 |
| Net Debt | -$103 | -$132 | -$151 | -$149 |